Antogen Raises Seed Funding
Antogen, a San Francisco-based company specializing in immunopeptidomics services, has announced the closure of its seed funding round on September 6, 2026. The company, which aids life science innovators in identifying and characterizing HLA-presented peptides for therapeutic discovery, biomarker development, and clinical research, secured an undisclosed amount in this round.
Investment Details
The seed round was led by iGrow Venture Partners. Details regarding other participating investors were not disclosed.
Company Leadership
Antogen was founded by Zachary Antovich, who also serves as the company's CEO. Under his leadership, the company has been at the forefront of providing expert services that translate peptide data into actionable insights for the life sciences sector.
Strategic Use of Funds
While specific plans for the new funds were not detailed, it is expected that Antogen will use the capital to enhance its service offerings and possibly expand its technological capabilities. Given the nature of its business, the funding may also support the advancement of research and development efforts in immunopeptidomics.
Conclusion
With this new infusion of capital, Antogen is well-positioned to continue its mission of supporting therapeutic discovery and clinical research, leveraging its specialized expertise in the life sciences industry.